1 Updates

Paid Rheumatoid Arthritis (RA) Clinical Trial Now Enrolling at Achieve Clinical Research in Birmingham, Alabama; Accepting M/F Patients with RA Age 18 - 75

Oct 16 2013, 4:18pm CDT | by PR.com

Achieve is conducting a study to evaluate the safety and efficacy of a new drug versus rituximab in patients with moderately to severely active rheumatoid arthritis (RA).

Birmingham, AL, October 16, 2013 --(PR.com)-- *To see if you qualify for this RA Clinical Trial in Alabama, visit Achieve Clinical Research on the web (http://www.achieveclinical.com/). There is no...

Filed under: news

Full Story below YouTube Videos

 
 

 

26 weeks ago

Paid Rheumatoid Arthritis (RA) Clinical Trial Now Enrolling at Achieve Clinical Research in Birmingham, Alabama; Accepting M/F Patients with RA Age 18 - 75

Oct 16 2013, 4:18pm CDT | by PR.com

Achieve is conducting a study to evaluate the safety and efficacy of a new drug versus rituximab in patients with moderately to severely active rheumatoid arthritis (RA).

Birmingham, AL, October 16, 2013 --(PR.com)-- *To see if you qualify for this RA Clinical Trial in Alabama, visit Achieve Clinical Research on the web (http://www.achieveclinical.com/). There is no cost to participate, no insurance is required, and you may receive compensation for time and travel.

Study Design

This is a 48-week, double-blind, multiple dose, parallel group trial to compare the safety, efficacy, immunogenicity and tolerability of an experimental drug to Rituxan and MabThera in patients with moderately to severely active RA. Patients will be enrolled across 250 clinical sites, in 26 countries.

Part I (48-week duration) will include 150 patients, which is considered sufficient for pharmacokinetics (PK) testing. Part II consists of a 48-week comparative safety/efficacy analyses with an additional 150 patients.

Background & Rationale

Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease characterized by synovial inflammation in the joints and consequently, progressive joint destruction. Depending on the severity of the disease, systemic manifestations may occur including lung disease, rheumatoid nodules and cardiovascular system effects. Without effective RA treatment, this disease may lead to severe functional disabilities, and therefore a considerable reduction in quality of life for the patient. The prevalence of RA varies with factors such as gender, race and smoking status and is approximately 0.5-1%.

B lymphocytes (B cells) are thought to play a crucial role in the pathogenesis of RA. They are also the primary source of rheumatoid factors (RFs) and anti-cyclic citrullinated peptide (anti-CCP) antibodies which contribute to the formation of immune complexes and complement activation in inflamed joints. Thus, B cell targeted therapy could play an important role in RA through a reduction in the B cell count as well as a reduction in B cell-mediated downstream effects on other cell types involved in the inflammatory response.

Primary Objectives

The primary objectives of this trial are:

To show PK similarity of this new drug to MabThera and Rituxan and of Rituxan to MabThera (three-way PK similarity).
To establish statistical equivalence of efficacy of this new drug and Rituxan/MabThera, in patients with moderately to severely active RA

Inclusion Criteria

Male or female participants, between 18 and 80 years of age, who have a diagnosis of moderately to severely active RA for at least 6 months

Patients must have had an inadequate response or intolerance to conventional DMARD therapy including at least one TNF inhibitor.

Positive for RF and/or anti-CCP antibodies.

Current treatment for RA on an outpatient basis:

-- Must be currently receiving and tolerating oral or parenteral MTX therapy at a dose of 15-25 mg per week (dose may be as low as 10 mg per week if the patient is unable to tolerate a higher dose) for at least 12 weeks immediately prior to Day 1.

-- Patients must be willing to receive oral folic acid (at least 5 mg/week or as per local practice) or equivalent during the entire study (mandatory co-medication for MTX treatment).

-- Biologic agents and DMARDs (other than MTX) must be withdrawn at least 2 weeks prior to Day 1.

-- Leflunomide must be withdrawn at least 8 weeks prior to Day 1 or a minimum of 2 weeks prior to Day 1 if after 11 days of standard cholestyramine washout.

-- If receiving current treatment with oral corticosteroids (other than intra-articular or parenteral), the dose must not exceed 10 mg/day prednisolone or equivalent. During the 4 weeks prior to Baseline (Day 1) the dose must remain stable.

-- Intra-articular and parenteral corticosteroids are not permitted within 6 weeks prior to Baseline Day 1 or throughout the trial, with the exception of IV administration of 100 mg methylprednisolone 30 to 60 minutes prior to each infusion
as this is part of the trial procedures.

-- Any concomitant non-steroidal anti-inflammatory drugs (NSAIDs) must be stable for at least 2 weeks prior to Day 1.

-- Patients may be taking oral hydroxychloroquine provided that the dose is not greater than 400 mg/day or chloroquine provided that the dose is not greater than 250 mg/day.

*Achieve Clinical Research conducts Phase II-IV Clinical Trials in Alabama. For more information about participating in an RA Clinical Study, please visit our website or contact us directly at (205) 380-6434.

Contact Information:
Achieve Clinical Research
Lashondra Cade
(205) 380-6434 320
Contact via Email
www.achieveclinical.com

Read the full story here: http://www.pr.com/press-release/520216

Press Release Distributed by PR.com

Source: PR.com

 

Don't miss ...

 

blog comments powered by Disqus

Latest stories

5 features an Amazon phone might offer
NEW YORK (AP) — Rumors of an Amazon smartphone reached a fever pitch this week, with the Wall Street Journal reporting that the device could be due out this year. Amazon hasn't confirmed that it has plans...
 
 
Why Drink Organic, Biodynamic And Sustainable Wines For Earth Day?
Six Organic Wines To Try Now Talking about organic wine is surprisingly complicated. When I set out to write this column I planned on rounding up some organic producers, tasting some wines and calling out the tastiest...
 
 
Washington's Anxiety as the President Heads to Asia
Anxiety is everywhere these days in the debate over U.S. policy toward Asia. Here in Washington, there seems to be deep anxiety about the Obama administration’s ability to fulfill its promise to rebalance to Asia. In...
 
 
'The Elder Scrolls Online' Hit With First Major Bug, The Infinite Dupe
When you make an MMO, you will eventually learn a hard lesson about how a single bug can derail your entire game. Right now, that’s exactly what’s happening with The Elder Scrolls Online. Players are rolling around in...
 
 
 

Latest from the Network

iOS 6 Users Facing Problems with FaceTime
The iOS 6 users are getting frustrated with the FaceTime, a popular video calling software, as it is continuing to crash in their iPhones and iPads.The users have informed the problem on a thread of Apple Support...
Read more on Apple Balla
 
Apple Offering Redesigned iPad Mini with Retina Display at 15% Discount
Apple brings a great offer for the iPad lovers, as the company decides to sell the refurbished model of iPad Mini with Retina display with a great discount of 15%.According to Apple Insider, the 16-GB model is being...
Read more on Apple Balla
 
SungardASVoice: Three Things Businesses Can Learn From The Decline Of American Idol
By Adam Wren Thirteen years into its prime-time run, “American Idol” is a brand in decline. But the kinds of things the show can do–and, in some cases, is doing–to change its fortunes can serve as an example to other...
Read more on Apple Balla
 
Justin Bieber crashed Drake Bell's party
Justin Bieber crashed Drake Bell's album party on Thursday night (04.17.14). The 20-year-old singer - who has been repeatedly attacked by the former Nickelodeon star on Twitter in recent months - went out of his way to...
Read more on Celebrity Balla
 
5 features an Amazon phone might offer
NEW YORK (AP) — Rumors of an Amazon smartphone reached a fever pitch this week, with the Wall Street Journal reporting that the device could be due out this year. Amazon hasn't confirmed that it has plans...
Read more on Business Balla
 
Asia's Week: Japan's Rebound Gets More Taxing
Another calamitous loss of human life gripped Asia’s attention this week, relegating economic matters to secondary notice, but they were also of concern. China’s growth pauses never cease to furrow brows but it is Japan...
Read more on Auto Balla
 
Why Drink Organic, Biodynamic And Sustainable Wines For Earth Day?
Six Organic Wines To Try Now Talking about organic wine is surprisingly complicated. When I set out to write this column I planned on rounding up some organic producers, tasting some wines and calling out the tastiest...
Read more on Business Balla
 
Washington's Anxiety as the President Heads to Asia
Anxiety is everywhere these days in the debate over U.S. policy toward Asia. Here in Washington, there seems to be deep anxiety about the Obama administration’s ability to fulfill its promise to rebalance to Asia. In...
Read more on Business Balla
 
'The Elder Scrolls Online' Hit With First Major Bug, The Infinite Dupe
When you make an MMO, you will eventually learn a hard lesson about how a single bug can derail your entire game. Right now, that’s exactly what’s happening with The Elder Scrolls Online. Players are rolling around in...
Read more on Business Balla
 
 
Auto Balla Sexy Balla Sport Balla TV Balla Politics Balla Movie Balla Apple Balla Business Balla Ad Balla Celebrity Balla